



Eni and Dompé farmaceutici join forces for health research

San Donato Milanese (Milan), 9 October 2023 – Eni CEO Claudio Descalzi and Dompé farmaceutici Executive Chairman Sergio Dompé today signed a Letter of Intent to launch joint research and development activities focusing on the health of people and communities in the areas where Eni operates, as well as other relevant global health issues.

Eni and Dompé farmaceutici decided to engage in joint research activities once again by pooling together their molecular modeling expertise and high-performance computing capabilities. This follows the two companies' participation in the European Exscalate4Cov project, aimed at identifying solutions to the issues emerged during the COVID-19 pandemic.

In line with the Letter of Intent, Eni will guarantee Dompé researchers access to its laboratories, support from the company's specialized staff, and use of its HPC5 supercomputer. The goal is accelerating the identification of new medicines and vaccines capable to respond more quickly and effectively to future healthcare emergencies. The Letter of Intent also encompasses the study of health security in relation to new energy supply chains, as well as periodic monitoring of high-incidence infections in area where Eni is present.

Today's signing represents a further step for Eni to ensure the management of the health and well-being of its people, based on the principles of precaution, prevention, and promotion of well-being set out in the Sustainable Development Goals of the United Nations 2030 Agenda.

Company Contacts:

Press Office: Tel. +39.0252031875 – +39.0659822030

Freephone for shareholders (from Italy): 800940924
Freephone for shareholders (from abroad): + 80011223456
Switchboard: +39-0659821

ufficio.stampa@eni.com
segreteriasocietaria.azionisti@eni.com
investor.relations@eni.com

Web site: www.eni.com

